IDEC-C2B8
Showing 26 - 50 of >10,000
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Seattle (drug, other, biological)
Completed
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Cyclophosphamide
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 18, 2022
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +9 more
- Quality-of-Life Assessment
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Feb 3, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 3, 2022
Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Chimeric Antigen Receptor T-Cell Therapy
- +3 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Mar 8, 2022
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 18, 2022
DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)
Not yet recruiting
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Bone Marrow Aspiration and Biopsy
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage Trial in Houston (Clofarabine,
Recruiting
- Acute Bilineal Leukemia
- +7 more
- Clofarabine
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
DLBCL Unclassifiable Trial in Houston (Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma Unclassifiable
- Cyclophosphamide
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Feb 23, 2022
DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6
Recruiting
- Diffuse Large B-Cell Lymphoma
- +2 more
- Prednisone
- +6 more
-
Tampa, Florida
- +1 more
Jan 12, 2022
Hematopoietic and Lymphoid System Tumor Trial in Houston (procedure, drug, biological, radiation)
Recruiting
- Hematopoietic and Lymphoid System Neoplasm
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2022
DLBCL, Transformed Follicular Lymphoma to DLBCL, Transformed Marginal Zone Lymphoma to DLBCL Trial in Columbus
Recruiting
- Diffuse Large B-Cell Lymphoma
- +2 more
- Cyclophosphamide
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Cyclophosphamide
- +9 more
-
Houston, TexasM D Anderson Cancer Center
Nov 2, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent
Completed
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +9 more
- Lenalidomide
- Rituximab
-
Houston, TexasM D Anderson Cancer Center
Sep 28, 2021
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,
Recruiting
- Burkitt Lymphoma
- +2 more
- Rituximab and Hyaluronidase Human
- +8 more
-
Kampala, UgandaUCI-Fred Hutch Cancer Centre
Mar 9, 2022
CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)
Active, not recruiting
- CD20 Positive
- +6 more
- Carboplatin
- +6 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 11, 2021
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large
Recruiting
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- +3 more
- Brentuximab Vedotin
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Feb 10, 2022
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma Trial in Sacramento (biological, radiation, procedure, drug)
Active, not recruiting
- Refractory Non Hodgkin Lymphoma
- Relapsed Non Hodgkin Lymphoma
- rituximab
- +7 more
-
Sacramento, CaliforniaUniversity of California Davis
Nov 28, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- DS-1594b
- +14 more
-
Houston, TexasM D Anderson Cancer Center
Oct 6, 2022
Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Scottsdale, Arizona
- +2 more
Jun 1, 2022
DLBCL Unclassifiable, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial in Duarte,
Recruiting
- Diffuse Large B-Cell Lymphoma Unclassifiable
- +6 more
- Carboplatin
- +4 more
-
Duarte, California
- +1 more
Oct 1, 2021
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in
Terminated
- Philadelphia Chromosome Negative
- +2 more
- Blinatumomab
- +11 more
-
Houston, TexasM D Anderson Cancer Center
Nov 3, 2022